Andrew See

Dr Andrew See

Radiation Oncologist
Become a Patient

Dr Andrew See is a confident and empathetic doctor committed to supporting patients throughout all stages of their journey. He prides himself in achieving the best possible outcome for his patients through supporting them make well-informed decisions about their treatment and communicating using plain language in a respectful and personable manner.


Dr Andrew See is an experienced radiation oncologist at Icon Cancer Centre Freemasons, Richmond, Moreland and Mulgrave.

His personal attributes have gained him a wide following among patients and referring physicians. Andrew is a confident and empathetic doctor who tries to understand what his patients are feeling and experiencing both physically and emotionally.

Dr See has been active in numerous clinical trials and acted as principal investigator in key studies investigating radiation therapy treatments for breast and prostate cancer. In June 2020, Dr See and Urologic Surgeon A/Prof Jeremy Grummet developed a new patient-centred treatment called focal brachytherapy, which is currently being used to treat men with low to intermediate risk prostate cancer. To complement the therapy, the LIBERATE clinical registry has been developed to monitor men who have undergone focal brachytherapy for prostate cancer. Findings from a retrospective study about this treatment is available to view here. The registry is Icon initiated research which operates out of Icon’s Epworth hospital sites.

Dr See has developed sub-discipline expertise with the management of breast, genitourinary cancers and general oncology, and has gained international training with stereotactic radiosurgery, a relatively new and expanding area of cancer medicine.

Affiliations & Memberships

  • Australian Medical Association (AMA)
  • Royal Australian and New Zealand College of Radiologists (RANZCR)

Special Interests

Dr Andrew See accepts referrals for all cancer types, with a special clinical interest in:
  • Breast cancer
  • Gastrointestinal cancer
  • Genitourinary cancer
  • Prostate cancer
  • Skin cancer
  • Stereotactic radiation therapy

Icon Locations

Epworth Freemasons View centre
Mulgrave View centre
Epworth Richmond View centre
Moreland View centre
Holmesglen View centre

Visiting Locations

  • Mildura


  • Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial. Patrick Bowden, Andrew W. See, Mark Frydenberg, Hodo Haxhimolla, Anthony J. Costello, Daniel Moon, Paul Ruljancich, Jeremy Grummet, Alan Crosthwaite, Ganes Pranavan, Justin S. Peters, Kevin So, Stella M. Gwini, Dean P. McKenzie, Skye Nolan, Lloyd M.L. Smyth, Craig Everitt. International Journal of Cancer, 2019 June.

  • Focal low dose-rate brachytherapy for low to intermediate risk prostate cancer: preliminary experience at an Australian institution. Elliot Anderson, Lloyd M. L. Smyth, Richard O’Sullivan, Andrew Ryan, Nathan Lawrentschuk, Jeremy Grummet, Andrew W. See. Translational Andrology and Urology 2021 September.